This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Eczema Prevention Study

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2008 by Oregon Health and Science University.
Recruitment status was:  Recruiting
National Eczema Association
Information provided by:
Oregon Health and Science University Identifier:
First received: December 8, 2008
Last updated: December 9, 2008
Last verified: December 2008
The purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic dermatitis.

Condition Intervention Phase
Atopic Dermatitis Drug: emollient (Cetaphil cream) Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis

Resource links provided by NLM:

Further study details as provided by Oregon Health and Science University:

Primary Outcome Measures:
  • Incidence of skin irritation [ Time Frame: 1 and 2 year time points ]
  • Incidence of skin infection [ Time Frame: 1 and 2 year timepoints ]
  • Compliance with protocol [ Time Frame: over two years ]

Secondary Outcome Measures:
  • Development of Eczema [ Time Frame: 1 and 2 year time points ]
  • Skin Barrier Function Measurements [ Time Frame: over 2 years ]

Estimated Enrollment: 25
Study Start Date: November 2006
Estimated Study Completion Date: November 2010
Estimated Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Emollient
Skin barrier protection from birth
Drug: emollient (Cetaphil cream)
Cetaphil cream applied daily from birth

Detailed Description:
All neonates will be treated with Cetaphil cream starting within 1 week of birth. All neonates enrolled will have an increased risk of developing atopic dermatitis because they have a family history of either asthma, hay fever, or atopic dermatitis. These neonates will then be followed for 2 years for the signs and symptoms of atopic dermatitis.

Ages Eligible for Study:   up to 1 Month   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • at least one parent diagnosed with Atopic Dermatitis
  • one parent or sibling with hayfever or asthma

Exclusion Criteria:

  • newborns with dermatitis at birth
  • newborns born greater than four weeks prematurely
  • newborns with medical problems necessitating prolonged hospitalization
  • newborns diagnosed with any immune deficiency syndrome
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00806221

Contact: Maureen Keene 503-228-7350

United States, Oregon
Oregon Health & Science University, Department of Dermatology Recruiting
Portland, Oregon, United States, 97239
Contact: Maureen Keene    503-228-7350      
Principal Investigator: Eric Simpson, MD         
Sub-Investigator: Jon Hanifin, MD         
Sub-Investigator: Alfons Krol, MD         
Sub-Investigator: Susan Tofte, RN, MS, FNP         
Sponsors and Collaborators
Oregon Health and Science University
National Eczema Association
Principal Investigator: Eric Simpson, MD Oregon Health and Science University
  More Information

Responsible Party: Eric Simpson, MD/ Principal Investigator, Oregon Health & Science University Identifier: NCT00806221     History of Changes
Other Study ID Numbers: IRB00002726
Study First Received: December 8, 2008
Last Updated: December 9, 2008

Keywords provided by Oregon Health and Science University:
Atopic Dermatitis
Skin Barrier

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Dermatologic Agents processed this record on June 26, 2017